The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival
Abstract
Background: Somatostatin analogs have been shown to control the growth of well-differentiated metastatic neuroendocrine tumors. Their effect on overall survival is a matter of debate. We analyzed the prognostic significance of early treatment with octreotide LAR and of hepatic tumor load in the PROMID trial cohort. Patients and Methods: Between 2001 and 2008, 85 treatment-naïve patients were randomly assigned to monthly octreotide LAR 30 mg or placebo until tumor progression or death. Post-study treatment was at the discretion of the investigator. Upon disease progression, 38 out of 43 placebo patients (88.4%) received octreotide LAR. For survival, patients were followed until May 2014. Results: Forty-eight out of 85 patients (56.5%) died. In 38 patients (79.2%), death was tumor related. The median overall survival (84.7 and 83.7 months) was only slightly different in patients assigned to octreotide and placebo [HR = 0.83 (95% CI: 0.47-1.46); p = 0.51]. The median overall survival was 84.7 months for all 85 patients, 107.6 months in the low-tumor-load (n = 64) and 57.5 months in the high-tumor-load (n = 21) subgroups [HR = 2.49 (95% CI: 1.36-4.55); p = 0.002]. There was a trend towards improved overall survival in patients with a low hepatic tumor load receiving octreotide compared to placebo [‘median not reached' and 87.2 months; HR = 0.59 (95% CI: 0.29-1.2); p = 0.142]. Conclusion: The extent of tumor burden is a predictor for shorter survival. Overall survival was similar in patients receiving octreotide LAR or placebo treatment at randomization. Crossover of the majority of placebo patients to octreotide LAR may have confounded the data on overall survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yao, J. C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J. E., Abdalla, E. K., Fleming, J. B., Vauthey, J.-N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4377 · Cited by 4,510
Rinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
Self-citationLanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,935
Garcia-Carbonero, R., Capdevila, J., Crespo-Herrero, G., Díaz-Pérez, J. A., Martínez del Prado, M. P., Alonso Orduña, V., Sevilla-García, I., Villabona-Artero, C., Beguiristain-Gómez, A., Llanos-Muñoz, M., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq022 · Cited by 419
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours
Pape, U.-F., Berndt, U., Muller-Nordhorn, J., Bohmig, M., Roll, S., Koch, M., Willich, S. N., & Wiedenmann, B. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0017 · Cited by 384
Jann, H., Roll, S., Couvelard, A., Hentic, O., Pavel, M., Müller‐Nordhorn, J., Koch, M., Röcken, C., Rindi, G., Ruszniewski, P., et al. (2011) · Cancer · doi:10.1002/cncr.25855 · Cited by 289
Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study
Ahmed, A., Turner, G., King, B., Jones, L., Culliford, D., McCance, D., Ardill, J., Johnston, B. T., Poston, G., Rees, M., et al. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-09-0042 · Cited by 274
Arnold, R., Rinke, A., Klose, K.-J., Müller, H.-H., Wied, M., Zamzow, K., Schmidt, C., Schade-Brittinger, C., Barth, P., Moll, R., et al. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00481-7 · Cited by 254
Self-citationArnold, R., Wilke, A., Rinke, A., Mayer, C., Kann, P. H., Klose, K., Scherag, A., Hahmann, M., Müller, H., & Barth, P. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.02.052 · Cited by 192
Self-citationEzziddin, S., Attassi, M., Yong-Hing, C. J., Ahmadzadehfar, H., Willinek, W., Grünwald, F., Guhlke, S., Biersack, H.-J., & Sabet, A. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.125336 · Cited by 191
Cited by
Brabander, T., van der Zwan, W. A., Teunissen, J. J. M., Kam, B. L. R., Feelders, R. A., de Herder, W. W., van Eijck, C. H. J., Franssen, G. J. H., Krenning, E. P., & Kwekkeboom, D. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2743 · Cited by 614
Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Strosberg, J. R., Caplin, M. E., Kunz, P. L., Ruszniewski, P. B., Bodei, L., Hendifar, A., Mittra, E., Wolin, E. M., Yao, J. C., Pavel, M. E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00572-6 · Cited by 578
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018
Shah, M. H., Goldner, W. S., Halfdanarson, T. R., Bergsland, E., Berlin, J. D., Halperin, D., Chan, J., Kulke, M. H., Benson, A. B., Blaszkowsky, L. S., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0056 · Cited by 375
Baum, R. P., Kulkarni, H. R., Singh, A., Kaemmerer, D., Mueller, D., Prasad, V., Hommann, M., Robiller, F. C., Niepsch, K., Franz, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24524 · Cited by 141
Metadata
- Authors
- Rinke, A., Wittenberg, M., Schade-Brittinger, C., Aminossadati, B., Ronicke, E., Gress, T. M., Müller, H.-H., Arnold, R., & for the PROMID Study Group
- Venue
- Neuroendocrinology
- Publisher
- S. Karger AG
- Published
- 2016-01-06
- Volume
- 104
- Issue
- 1
- Pages
- 26-32
- ISSN
- 0028-3835 (ISSN-L)
- 1423-0194
- OpenAlex
- W2232569012
- Cited by
- 377
- References
- 11
- FWCI
- 29.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. https://app.cochat.ai/papers/10.1159/000443612
- The paper
- Rinke, A., Wittenberg, M., Schade-Brittinger, C., Aminossadati, B., Ronicke, E., Gress, T. M., Müller, H.-H., Arnold, R., & for the PROMID Study Group. (2017). Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology. https://doi.org/10.1159/000443612
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.